CML Experts in Canada - Experts LMC au Canada
( Note: this list is not exhaustive)
CML Experts in Quebec - Experts LMC au Quebec
(Montreal - Quebec City - Sherbrooke)
(Montreal - Quebec City - Sherbrooke)
Hôpital Général Juif de Montréal
Hôpital Général Juif de Montréal Hôpital Maisonneuve-Rosemont (Montréal) Hôpital Maisonneuve-Rosemont (Montréal) Hôpital Maisonneuve-Rosemont (Montréal) Hôpital Maisonneuve-Rosemont (Montréal) Hôpital Royal-Victoria (Montréal) Centre hospitalier universitaire de Sherbrooke Centre hospitalier universitaire de Sherbrooke Hôpital de l’Enfant-Jésus (Ville de Québec) CHU Pavillon Hôtel-Dieu de Québec (Québec) |
Vertical Divider
CML Experts in Ontario - Experts LMC en Ontario
Princess Margaret Hospital (Toronto)
Princess Margaret Cancer Centre (Toronto) Ottawa Hospital |
Vertical Divider
CML Experts in British Columia- Experts LMC en Colombie Britannique
Dr. Donna L. Forrest
Dr. John Shepherd
Dr. Kirk Schultz
Dr. David Sanford
CML Experts in Nova Scotia- Experts LMC en Nouvelle Écosse
Dr. Conrad Vincent Fernandez
Dr. Conrad Vincent Fernandez
CLINICAL TRIALS
Treatment-free Remission Accomplished With Dasatinib in Patients With CML (Nova Scotia)
Stopping Tyrosine Kinase Inhibitors in Affecting Treatment-Free Remission in Patients With Chronic Phase Chronic Myeloid Leukemia (Nova Scotia)
A Study Investigating the Predictive Value of Philadelphia Positive Stem Cell Properties in Newly Diagnosed Patients With Chronic Myeloid Leukemia in Chronic Phase Receiving Treatment With Imatinib ( British Columbia)
Study of Efficacy of CML-CP Patients Treated With ABL001 Versus Bosutinib, Previously Treated With 2 or More TKIs (Novartis)
Study of Efficacy and Safety of Asciminib in Combination With Imatinib in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP) – (Novartis)
Study to Allow Access to Nilotinib for Patients Who Are on Nilotinib Treatment in a Novartis-sponsored Study (British Colombia, Ontario, NovaScotia)
Study to Allow Access to Nilotinib for Patients Who Are on Nilotinib Treatment in a Novartis-sponsored Study
Treatment-free Remission Accomplished With Dasatinib in Patients With CML (Nova Scotia)
Stopping Tyrosine Kinase Inhibitors in Affecting Treatment-Free Remission in Patients With Chronic Phase Chronic Myeloid Leukemia (Nova Scotia)
A Study Investigating the Predictive Value of Philadelphia Positive Stem Cell Properties in Newly Diagnosed Patients With Chronic Myeloid Leukemia in Chronic Phase Receiving Treatment With Imatinib ( British Columbia)
Study of Efficacy of CML-CP Patients Treated With ABL001 Versus Bosutinib, Previously Treated With 2 or More TKIs (Novartis)
Study of Efficacy and Safety of Asciminib in Combination With Imatinib in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP) – (Novartis)
Study to Allow Access to Nilotinib for Patients Who Are on Nilotinib Treatment in a Novartis-sponsored Study (British Colombia, Ontario, NovaScotia)
Study to Allow Access to Nilotinib for Patients Who Are on Nilotinib Treatment in a Novartis-sponsored Study